Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 20/20 | 0.77 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.74 |
| ▸ | FLT3 | P36888 | 1/20 | 0.74 |
| ▸ | CDK9 | P50750 | 1/20 | 0.74 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.74 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.74 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20720884 | 0.94 | TBK1 (0.77) | TBK1CCNT1FLT3CDK9IKBKE | |
| SCHEMBL20720927 | 0.93 | TBK1 (0.78) | TBK1CCNT1FLT3CDK9IKBKE | |
| SCHEMBL20721048 | 0.92 | TBK1 (0.77) | TBK1CCNT1FLT3CDK9IKBKE | |
| SCHEMBL20720911 | 0.92 | TBK1 (0.78) | TBK1CCNT1FLT3CDK9IKBKE | |
| SCHEMBL20720881 | 0.91 | TBK1 (0.79) | TBK1CCNT1FLT3CDK9IKBKE | |
| SCHEMBL20720933 | 0.91 | TBK1 (0.78) | TBK1CCNT1FLT3CDK9IKBKE | |
| SCHEMBL20720857 | 0.90 | TBK1 (0.75) | TBK1CCNT1FLT3CDK9IKBKE | |
| SCHEMBL20720873 | 0.90 | TBK1 (0.75) | TBK1CCNT1FLT3CDK9IKBKE | |
| SCHEMBL19005154 | 0.90 | TBK1 (0.75) | TBK1CCNT1FLT3CDK9IKBKE | |
| SCHEMBL20721014 | 0.89 | TBK1 (0.77) | TBK1CCNT1FLT3CDK9IKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | CCNI, CCNT2, CDK2 | TBK1 1468/4885CCNT1 5/4885FLT3 438/4885 |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | CCNI, CCNT2, CDK2 | TBK1 1468/4885CCNT1 5/4885FLT3 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.